Teva Pharmaceutical Industries Limited (TEVA) stock moves -23.06% down in last quarter

Dianna Christensen
August 5, 2017

(NYSE:NWL). At the time of writing, the First Call consensus price target for the company is $58.76.

Other hedge funds also recently modified their holdings of the company.

The share of Teva Pharmaceutical Industries Limited (TEVA) now has a value of $23.75 while the company's 52 week low is at $27.59, the shares dropped to the 52 week low on 08/03/17.

Teva Pharmaceutical Industries Limited (TEVA) has the market capitalization of $24.4 Billion. CIBC restated a "buy" rating and set a $43.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, April 7th. The company has analyst rating of 2.50 on scale of 1-5. Migdal Insurance & Financial Holdings Ltd. now owns 4,564,560 shares of the company's stock valued at $165,461,000 after buying an additional 801,106 shares during the period. While the company's share hit the 52 week high on 08/05/16 stationing the value of $55.79. Extending back, their stock is trading -31.86% from the 50-Day Simple Moving Average, looking even further back, they are trading -37.95% off of the 200-Day Simple Moving Average.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%.

Two killed after Indian troops open fire on civilians in held Kashmir
Khan said the trapped militants fired at the troops, triggering a gunbattle which lasted at least two hours. India accuses Pakistan of arming and training the rebels, which Pakistan denies.

'Harry Potter' Playwright Trades Wands For Lightsabers, Signs On With 'Star Wars'
Little is known about the movie at this point, and details will obviously remain slim until The Last Jedi has had its premiere. It won a record-breaking number of Olivier Awards, and printed copies of the script also broke sales records .

White House pushes 'aggressive' timeline for tax cut
The lower rate would also apply to small businesses now taxed as individuals, which often face a top rate of close to 50 percent. One proposal would require companies with at least 500 workers to offer coverage, up from the Obama law's cutoff of 50 workers.

Teva, which bought Allergan's generics business for $40.5 billion in August, was expected by analysts to have earned $1.06 per share on revenue of $5.72 billion, according to Thomson Reuters I/B/E/S Estimates. Company shares were recently noted -17.80% off of the 50-day high and -0.44% away from the 50-day low. Revenue was also below the mark at $5.69 billion versus analysts' projections of $5.72 billion. Finally, Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a "sell" rating to a "hold" rating in a research report on Monday, April 17th. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & global copyright & trademark law. If you are viewing this article on another website, it was stolen and republished in violation of USA & worldwide copyright & trademark legislation. Teva Pharmaceutical Industries Limited makes up about 1.7% of Blue Granite Capital LLC's portfolio, making the stock its 28th largest position. "We would be more positive on Teva shares if generic drug pricing improves and/or the brand drug launches and pipeline advancements exceed expectations". Sii Investments Inc. WI now owns 6,739 shares of the company's stock valued at $214,000 after buying an additional 25 shares during the last quarter.

Teva suffered another major blow on Thursday as the New York Supreme Court threw out the company's claim that it had been defrauded in the acquisition of Mexican company Rimsa Pharmaceuticals for $2.3 billion in 2015.

The number of shares changed hands in the stock is good, indicating the interest and low risk associated with it. 106,521,764 shares of the company were exchanged.

On news of the earnings, Teva stock dropped 24% to $23.75, the lowest price since November 2004. It revised its earnings per share forecast for the year to $4.30-$4.50, from a previous outlook of $4.90-$5.30 a share. ST Germain D J Co. Bank Hapoalim BM now owns 11,673 shares of the company's stock valued at $375,000 after buying an additional 980 shares during the period. Institutional investors own 56.20% of the company's stock. For example, an established blue chip company in a mature industry with stable earnings will most likely have a much lower beta compared to a start up Biotechnology Company.

The Israel-based company, which operates its North American division out of Montgomery County headquarters, plans to close 15 plants and lay off 7,000 employees over the next two years. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Other reports by GlobalViralNews

Discuss This Article